| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00865904 | Cystic Fibrosis | Drug: VX-809|Drug: Placebo | Vertex Pharmaceuticals Incorporated | Phase 2 | 2009-03-01 | 2015-08-01 |
| NCT01216046 | Cystic Fibrosis | Drug: VX-809|Drug: VX-770|Drug: VX-809 placebo|Drug: VX-770 placebo | Vertex Pharmaceuticals Incorporated | Phase 1 | 2010-10-01 | 2012-01-16 |
| NCT00966602 | Cystic Fibrosis | Drug: VX-809|Drug: VX-770|Drug: VX-809 & VX-770|Drug: Placebo | Vertex Pharmaceuticals Incorporated | Phase 1 | 2009-09-01 | 2010-01-02 |
| NCT01225211 | Cystic Fibrosis | Drug: Lumacaftor|Drug: Ivacaftor|Drug: Lumacaftor Placebo|Drug: Ivacaftor Placebo | Vertex Pharmaceuticals Incorporated | Phase 2 | 2010-10-01 | 2015-09-02 |
| NCT01899105 | Cystic Fibrosis | Drug: lumacaftor|Drug: ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 1 | 2013-07-01 | 2014-04-02 |
| NCT01897233 | Cystic Fibrosis | Drug: Lumacaftor|Drug: Ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2013-07-01 | 2016-10-07 |
| NCT02807415 | Cystic Fibrosis | Drug: Lumacaftor plus Ivacaftor | Hannover Medical School|Heidelberg University|University of Giessen | | 2016-06-01 | 2016-06-22 |
| NCT01768663 | Cystic Fibrosis | Drug: Lumacaftor|Drug: Ivacaftor|Drug: Ciprofloxacin|Drug: Itraconazole|Drug: Rifampin | Vertex Pharmaceuticals Incorporated | Phase 1 | 2013-01-01 | 2013-11-14 |
| NCT02390219 | Cystic Fibrosis|Advanced Lung Disease | Drug: Lumacaftor|Drug: Ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2015-03-01 | 2016-10-26 |
| NCT01931839 | Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation | Drug: Lumacaftor|Drug: Ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2013-10-01 | 2016-04-27 |
| NCT02514473 | Cystic Fibrosis | Drug: VX-809|Drug: Placebo|Drug: VX-770 | Vertex Pharmaceuticals Incorporated | Phase 3 | 2015-07-01 | 2016-10-24 |
| NCT01807923 | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor|Drug: Placebo | Vertex Pharmaceuticals Incorporated | Phase 3 | 2013-05-01 | 2015-08-01 |
| NCT01807949 | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Drug: Placebo|Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2013-04-01 | 2016-08-15 |
| NCT01910415 | Cystic Fibrosis | Drug: Lumacaftor|Drug: Lumacaftor Placebo|Drug: Ivacaftor|Drug: Ivacaftor Placebo|Drug: moxifloxacin hydrochloride | Vertex Pharmaceuticals Incorporated | Phase 1 | 2013-06-01 | 2014-08-08 |
| NCT02653027 | Diabetes|Cystic Fibrosis | Drug: Lumacaftor-ivacaftor|Other: OGTT | Massachusetts General Hospital | | 2016-01-01 | 2016-01-08 |
| NCT02858843 | Cystic Fibrosis|Diabetes | Drug: lumacaftor-ivacaftor | Massachusetts General Hospital | | 2016-08-01 | 2016-08-15 |
| NCT02544451 | Cystic Fibrosis | Drug: Ivacaftor|Drug: Lumacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2015-08-01 | 2016-12-19 |
| NCT02797132 | Cystic Fibrosis | Drug: lumacaftor/ ivacaftor | Vertex Pharmaceuticals Incorporated | Phase 3 | 2016-05-01 | 2016-07-22 |
| NCT01888393 | Hepatic Impairment|Healthy | Drug: lumacaftor 200 mg q12h + ivacaftor 250 mg q12h | Vertex Pharmaceuticals Incorporated | Phase 1 | 2013-06-01 | 2013-11-18 |
| NCT02823470 | Cystic Fibrosis | Drug: LUM/IVA|Device: activated smart device|Device: de-activated smart device | Vertex Pharmaceuticals Incorporated | Phase 4 | 2016-06-01 | 2017-03-22 |
